Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the publication of preclinical data validating Acyl-CoA Synthetase 5 (ACSL5) as a target for obesity and chronic weight management. The ...

Lexicon Pharmaceuticals, Inc. currently offers three late-stage assets Zynquista, Inpefa & Pilavapadin. Learn more about LXRX ...

Detailed price information for Lexicon Pharmaceutcl (LXRX-Q) from The Globe and Mail including charting and trades.

Lexicon Pharmaceuticals (LXRX) announced the publication of preclinical data validating Acyl-CoA Synthetase 5 as a target for obesity and chronic ...

I don’t feel like I’m dragging anymore.” So far, he has experienced no side effects and plans to continue microdosing as long ...

Can Novo Nordisk get its comeback going in 2026? Let's discuss two things that could materialize for the company next year ...

Denmark on Thursday sharply raised its economic growth forecast for 2025, due in part to the pharmaceuticals industry, which ...

Danish drugmaker Novo Nordisk will launch its blockbuster diabetes drug Ozempic in India this month, three sources familiar ...

The price/sales TTM, EV/Sales TTM, and EV/EBITDA TTM of Novo, as compared to its peers, repeat substantially the same story ...

CHONGQING, CHINA - SEPTEMBER 10: In this photo illustration, the logo of Novo Nordisk is displayed on a smartphone screen on September 10, 2025 in Chongqing, China. The maker of Wegovy and Ozempic, ...

The Roundhill GLP-1 & Weight Loss ETF (NASDAQ: OZEM) sits squarely at the center of Monday's shock. The fund's top weights — Eli Lilly at 18.72% and Novo Nordisk at 13.23% — mean that more than ...

A proposed new federal law could provide some competitive guardrails for the company's most important product.